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Background: Sleep disorder has a close interaction with pulmonary hypertension (PH). Obstructive sleep apnea (OSA) can cause and worsen PH, 
and right heart dysfunction due to PH can induce central sleep apnea (CSA) and may aggravate clinical conditions. In this study, how treatment of 
PH can change OSA and CSA, was investigated.
Methods: Forty-nine patients with PH (46 ± 15 years old, mean pulmonary artery pressure 50 ± 14mmHg) underwent right heart catheterization 
(RHC) and sleep study with simplified polysomnography (PSG) using nasal respiration monitor, chest and abdominal movement detector and oxygen 
saturation measurement.
Results: Sleep apnea syndrome (SAS) was noted in 38 patients (78%) when apnea-hypopnea index (AHI) more than 5 is defined as SAS. OSA 
was found in 7 patients, CSA in 12 and both OSA and CSA (BSA) in 30 before the treatment. Oxygen was administered to 10 patients with CSA or 
BSA before the treatment, resulting in an improvement of AHI in 9 out of 10 patients (AHI: 16 ± 8 to 5 ± 3; p<0.05). One patient with severe OSA 
(AHI: 24) started continuous positive airway pressure therapy with success. The remaining 27 patients had epoprestenol and/or bosentan and/or 
sildenafil, and underwent RHC and simplified PSG (average observational period: 14 ± 8 months) after the treatment. AHI was reduced from 11 ± 11 
to 5 ± 6 in 14 patients with a decrease in pulmonary vascular resistance (PVR) from 20 ± 12 to 10 ± 6 units, and AHI did not change in 1 patient 
without a change in PVR. AHI increased in 5 patients with a decrease in PVR, and AHI decreased in 2 patients with an increase in PVR. AHI increased 
in 1 patient and decreased in 4 patients without a change in PVR.
Conclusions: In 49 PAH patients, about 78% had SAS including OSA in 18%, CSA in 32% and both types in 50%. Nine out of 10 patients with 
oxygen therapy showed a remarkable improvement in SAS. About one half of the remaining patients showed an improvement of apnea following 
medical therapy.
